3d agoThe FlyBULLISH 63Product/PR
Archived explainer. For the current picture see today's ELAN page.
Why Is ELANCO ANIMAL HEALTH (ELAN) Stock Down Today?
By the Top Tier Newswire AI Desk · August 7, 2026 at 3:20 PM ET · reviewed against 3 wire stories
ELANCO ANIMAL HEALTH (ELAN) is down -7.29% in the latest session. Our newswire has captured 3 stories on ELAN across 3 sources in the last 36 hours, with AI sentiment reading bullish (avg 63/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Why ELAN stock is down today
Elanco Animal Health's stock fell 7.29% to $22.43 in a volatile session marked by a sharp intraday decline. The move followed the FDA's emergency use authorization for Elanco's CLiK Extra wound spray, a product designed to prevent New World Screwworm infestations in livestock and wildlife. While the authorization is a regulatory milestone, the stock's performance suggests the market may be viewing the news with caution amid broader financial concerns.
What Happened
Elanco received the FDA's emergency use authorization for CLiK Extra, which allows the product to be used on or around wounds to prevent New World Screwworm infestations in a variety of animals. The company emphasized the importance of vigilance and early intervention in minimizing animal injury and limiting the parasite's spread. Despite the regulatory approval, the stock opened at $24.26 and reached a high of $25.37 before declining throughout the session to close near $22.43.
The stock's decline occurred even as some analysts have maintained positive coverage of the company. UBS and Keybanc have both raised their price targets for Elanco, with UBS setting a $33 target and Keybanc at $30. However, the stock's reaction indicates that investors may be factoring in Elanco's ongoing financial challenges, including a net loss for the trailing twelve months and a negative earnings per share.
What The Data Shows
Elanco's stock opened near its 52-week high but fell sharply to close near the lower end of its 52-week range. The session saw a volume of 13.5 million shares, more than double the 3-month daily average. This suggests increased investor activity and potentially mixed sentiment. Meanwhile, recent insider transactions show two executives purchasing shares on May 15, 2026, for a total of $200K, indicating some confidence in the company's direction.
What To Watch
Elanco has not scheduled earnings in the immediate future. Investors will likely monitor coverage breadth and analyst commentary for further signs of market sentiment.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
ELAN by the numbers
Last: $22.43Session: -7.29%Coverage: 3 stories / 3 sourcesAI sentiment: 63/100 (bullish)Mkt cap: $13.1B52w: $13.76 to $27.98
The headlines behind the move
3d agoPR NewswireBULLISH 59Product/PR
Elanco's CLiK™ Extra (dicyclanil topical suspension) Wound Spray Receives FDA Emergency Use Authorization for Application on or Around Wounds for Prevention of New World Screwworm in Variety of Livestock and Captive and Captured Wildlife Species
Vigilance and early intervention are key to minimizing animal injury and limiting the parasite's spread, according to Elanco's technical experts Emergency Use Authorization for Elanco's CLiK Extra provides livestock producers with a vital tool in the prevention of New World screwworm...
3d agoSeeking AlphaBULLISH 67Product/PR
Elanco granted FDA’s emergency nod for new world screwworm drug
Elanco Animal Health (ELAN) wins the FDA's emergency use authorization for CLiK Extra as a treatment to prevent new world screwworm infestations. Read more here.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on ELAN: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier ELAN move explainers: 2026-08-10 · 2026-08-07